<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04687358</url>
  </required_header>
  <id_info>
    <org_study_id>KPL-914-Reg-001</org_study_id>
    <nct_id>NCT04687358</nct_id>
  </id_info>
  <brief_title>REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients</brief_title>
  <acronym>RESONANCE</acronym>
  <official_title>Registry of the Natural History of Recurrent Pericarditis in Pediatric and Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kiniksa Pharmaceuticals (UK), Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kiniksa Pharmaceuticals, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The registry will focus on furthering the understanding of the natural history of recurrent&#xD;
      pericarditis (RP), as well as document RP-related clinical, health-related quality of life&#xD;
      (HRQoL), and economic burden and will assist the medical community to refine or develop&#xD;
      data-driven recommendations for clinical management of RP patients to optimize clinical&#xD;
      outcomes. It also aims to generate data in support of the impact of rilonacept on clinical&#xD;
      outcomes in a real-world population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2021</start_date>
  <completion_date type="Anticipated">February 2026</completion_date>
  <primary_completion_date type="Anticipated">February 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Patients using 1 or more RP treatments</measure>
    <time_frame>5 years</time_frame>
    <description>Proportion of patients using 1, 2, 3, or more concomitant RP treatments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Most frequently used RP treatments</measure>
    <time_frame>5 years</time_frame>
    <description>Number of subjects who used each treatment recorded during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in the use of corticosteroids</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline through end of observation in corticosteroid use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in RP activity</measure>
    <time_frame>1 year</time_frame>
    <description>Change from baseline in RP disease recurrences within 1 year (from 1 year prior to baseline to 1 year after baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pericardial rub</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in pericardial rub</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pericardial effusion</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in pericardial effusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fever</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in fever</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dyspnea</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in dyspnea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-reactive protein (CRP)</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in erythrocyte sedimentation rate (ESR)</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in ESR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in white blood count (WBC)</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in WBC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin-1 (IL-1)</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in IL-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin-6 (IL-6)</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in electrocardiogram (ECG)</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in ST-, PR-, QRS- and QT- intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in echocardiogram</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in chest x-ray</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in chest x-ray</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac magnetic resonance imaging (cMRI)</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in cMRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiovascular magnetic resonance (CMR) imaging</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in CMR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidetector (cardiac) computed tomography (MDCT)</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in MDCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>5 years</time_frame>
    <description>Rate of adverse events reported by PC treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PROMIS-29 patient-reported outcomes</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in PROMIS-29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PROMIS Pediatric/Parent 25 patient-reported outcomes</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in PROMIS Pediatric/Parent 25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in insomnia severity index (ISI) patient-reported outcomes</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in ISI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Patient Global Impression of Pericarditis Severity (PGIPS) patient-reported outcomes</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in PGIPS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in persistent pericarditis numerical rating scale (PPNRS) patient-reported outcomes</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in PPNRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in D12 patient-reported outcomes</measure>
    <time_frame>5 years</time_frame>
    <description>Change from baseline in D12 outcome measures</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Recurrent Pericarditis</condition>
  <arm_group>
    <arm_group_label>Active RP</arm_group_label>
    <description>Patients who are currently under the care of a physician for treatment of RP, currently on treatment for RP, and have had an episode (recurrence of typical pericarditis pain associated with supportive objective evidence of pericarditis) in the last 3 years prior to enrollment. Once included in the registry, these patients will have both retrospective and prospective follow-up and data collection (hybrid design).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactive RP</arm_group_label>
    <description>Patients who have had a diagnosis of RP, have not had an episode for 3 years and have not been prescribed any treatment for RP in the last 3 years, prior to enrolling in the registry. Once included in the registry, data collected from these patients will be retrospective only.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with active or inactive recurrent pericarditis who have participated in the&#xD;
        RHAPSODY (KPL-914-C002) Phase 3 clinical study of rilonacept and patients from sites who&#xD;
        have expressed an interest in the registry will be included. In addition, RESONANCE will&#xD;
        also include decentralized sites for remote patients who wish to participate in the&#xD;
        registry but are not near a registry site.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        ACTIVE RP PATIENTS&#xD;
&#xD;
        Select Inclusion Criteria:&#xD;
&#xD;
          -  Physician-confirmed (or confirmation in medical records) diagnosis of RP defined as an&#xD;
             initial, acute, episode and at least one pericarditis recurrence after the initial&#xD;
             acute episode&#xD;
&#xD;
          -  Experienced at least one pericarditis episode in the 3 years prior to inclusion&#xD;
&#xD;
          -  Under the care of a physician for the treatment and management of RP&#xD;
&#xD;
          -  Currently prescribed medication for RP&#xD;
&#xD;
        Select Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of pericarditis secondary to tuberculosis (TB), cancer if not in full&#xD;
             remission, post thoracic blunt trauma (e.g., motor-vehicle accidents), myocarditis,&#xD;
             systemic autoimmune diseases, except SJIA and adult Still's disease, HIV&#xD;
&#xD;
          -  Appears to have an impairment (e.g., cognitive, hearing, visual) or insufficient&#xD;
             English or Spanish proficiency that could interfere with ability to complete&#xD;
             patient-completed assessments&#xD;
&#xD;
          -  Currently enrolled in a therapeutic investigational drug or device study&#xD;
&#xD;
        INACTIVE RP PATIENTS&#xD;
&#xD;
        Select Inclusion Criteria:&#xD;
&#xD;
          -  Physician-confirmed (or confirmation in medical records) diagnosis of RP defined as an&#xD;
             initial, acute, episode and at least one pericarditis recurrence after the initial,&#xD;
             acute episode&#xD;
&#xD;
          -  Patient had a last episode occurring at least 3 years and up to 5 years before&#xD;
             registry inclusion&#xD;
&#xD;
          -  Resolution of RP symptoms confirmed with no further RP treatment for 3 years prior to&#xD;
             registry enrollment&#xD;
&#xD;
        Select Exclusion Criteria:&#xD;
&#xD;
          -  Experienced a pericarditis episode within 3 years from enrolling in the registry&#xD;
&#xD;
          -  Currently receiving RP treatment prescribed by a treating physician (e.g., CS,&#xD;
             colchicine)&#xD;
&#xD;
          -  Diagnosis of pericarditis secondary to tuberculosis (TB), cancer if not in full&#xD;
             remission, post thoracic blunt trauma (e.g., motor-vehicle accidents), myocarditis,&#xD;
             systemic autoimmune diseases except SJIA and adult Still's disease, HIV&#xD;
&#xD;
          -  Enrolled in a therapeutic investigational clinical trial during the observation period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Dana Martin, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Kiniksa Pharmaceuticals Corp</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alison Reid</last_name>
    <phone>7814319100</phone>
    <email>areid@kiniksa.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Ebnet</last_name>
      <phone>612-863-3833</phone>
    </contact>
    <investigator>
      <last_name>David Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - PPDS</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>507-422-6246</phone>
      <email>davison.halley@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Luis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital/Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>314-286-1767</phone>
      <email>Karen.bult@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Amanda Verma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TKL Research Inc.</name>
      <address>
        <city>Fair Lawn</city>
        <state>New Jersey</state>
        <zip>07410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uzoma Okamgba-Nwoke</last_name>
      <phone>201-587-0500</phone>
      <phone_ext>2548</phone_ext>
      <email>unwoke@tklresearch.com</email>
    </contact>
    <investigator>
      <last_name>Steven Schreiber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>212-263-0855</phone>
      <email>Alexander.Auchus@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Michael Garshick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health - Lenox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>212-434-4174</phone>
      <email>estrober@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Finkielstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>216-445-9007</phone>
      <email>MIHALUS@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Paul Cremer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Legacy Hospital and Health Center DBA Legacy Research Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>503-413-1612</phone>
      <email>kkummer@lhs.org</email>
    </contact>
    <investigator>
      <last_name>Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carnegie Mellon University, Allegheny Health Network, Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geetha Rayarao</last_name>
      <phone>412-359-4076</phone>
    </contact>
    <investigator>
      <last_name>Robert Biederman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>804-828-2775</phone>
      <email>Emily.Federmann@vcuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Georgia Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>206-987-1014</phone>
      <email>Deepthi.Nair@seattlechildrens.org</email>
    </contact>
    <contact_backup>
      <email>Hademi.kajimoto@seattlechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Portman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pericarditis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

